Progyny (PGNY) Cash & Equivalents (2018 - 2026)

Progyny (PGNY) has 9 years of Cash & Equivalents data on file, last reported at $131.6 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $131.6 million, up 20.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $131.6 million (up 20.48% YoY), and the FY2025 annual result was $112.2 million, down 30.85% from the prior year.
• Cash & Equivalents rose to $131.6 million in Q1 2026 per PGNY's latest filing, from $112.2 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $170.6 million in Q2 2023 and troughed at $38.8 million in Q1 2022.
• A 5-year average of $114.7 million and a median of $115.0 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents soared 300.09% in 2023, then plunged 44.33% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $120.1 million in 2022, then dropped by 18.97% to $97.3 million in 2023, then soared by 66.82% to $162.3 million in 2024, then sank by 30.85% to $112.2 million in 2025, then grew by 17.26% to $131.6 million in 2026.
• Business Quant data shows PGNY's Cash & Equivalents at $131.6 million in Q1 2026, $112.2 million in Q4 2025, and $134.0 million in Q3 2025.